New hope for stomach cancer: targeted drug combo under study
NCT ID NCT07427992
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a drug called zolbetuximab combined with standard chemotherapy in people with a specific type of advanced stomach cancer that has spread. The cancer must have a protein called claudin 18.2 on at least 75% of its cells and be HER2-negative. The goal is to see how well the treatment works in real-world settings, outside of a controlled clinical trial. About 70 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zolbetuximab (a targeted antibody) combined with chemotherapy (FOLFOX or XELOX)
What this could lead to
If it works, this could provide a new treatment option for people with a specific type of advanced stomach cancer that is hard to treat.
What could go wrong
This is an early real-world study, not a large randomized trial, so results may be less reliable. The treatment may not improve survival and could cause side effects from chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
European Institute of Oncology
RECRUITINGMilan, 20141, Italy
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact